Printer Friendly

DISTRICT COURT ISSUES INJUNCTION IN PATENT DISPUTE

 Advanced Interventional Systems Seeks Immediate Stay of Injunction
 While Preparing to Appeal Jury Verdict
 IRVINE, Calif., Dec. 23 /PRNewswire/ -- The following is being issued by Advanced Interventional Systems (NASDAQ: LAIS):
 A judge in a district court in Virginia denied the post-trial motions recently filed by Advanced Interventional Systems in a patent lawsuit in which LAIS was found by the jury to infringe one claim of one patent asserted by Pillco Limited Partnership, the plaintiff in the dispute.
 According to LAIS' chief financial officer, Richard B. Crosby, the judge also issued an injunction which requires the company to immediately refrain from manufacturing and selling additional product. LAIS expects to file a motion this week to request a stay of the injunction in a federal appeals court, while it simultaneously files a notice of appeal. Unless the injunction is removed, LAIS is prohibited from manufacturing or selling its product, the first laser system approved by the Food and Drug Administration for commercial use to clear blocked arteries in the heart.
 Crosby said the injunction issued by the court represents a serious situation for LAIS. The company's legal counsel is working expeditiously to resolve the issue of the injunction as soon as possible.
 "To seek immediate relief from the injunction ordered by the court on Monday, Dec. 21, we are asking the federal court today for a stay of the injunction, effective without delay, while the appeal process is initiated," said Crosby.
 The company has several non-commercial products in clinical use as allowed under investigational device exemptions (IDEs). It is management's belief, based on legal opinion, that federal statute protects such products from patent disputes, Crosby said.
 "From the onset of the company's initial conversations with Pillco in 1990, management has never believed LAIS infringed any valid claims at issue in this legal dispute. We still maintain that belief, which is the basis for the appeal we are preparing to file in the federal appeals court. We hope to convince the federal appeals court that the jury verdict issued on Friday, Nov. 20, in which LAIS was found to infringe one claim of one patent, was in error," he said.
 The district court found no infringement on two patents at issue, no willful infringement on any patents and determined zero past damages.
 LAIS received approval from the Food and Drug Administration to sell its excimer laser system to treat coronary artery disease in January 1992.
 -0- 12/23/92
 /CONTACT: Connie McCluskey, director of corporate communications of Advanced Interventional Systems, 714-586-1342 or 714-581-8510, ext. 234/
 (LAIS)


CO: Advanced Interventional Systems; Pillco Limited Partnership ST: California IN: MTC SU:

JL -- NYON2 -- 9443 12/23/92 09:03 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 23, 1992
Words:444
Previous Article:VOLT INFORMATION SCIENCES AND DU PONT PRINTING AND PUBLISHING DISCONTINUE NEGOTIATIONS
Next Article:TONY VINCIQUERRA NAMED VICE PRESIDENT AND GENERAL MANAGER OF GROUP W'S KYW-TV IN PHILADELPHIA
Topics:


Related Articles
PRELIMINARY INJUNCTIONS GRANTED TO PRESERVE STATUS QUO PENDING ARBITRATION OF PATENT LICENSE DISPUTE BETWEEN DISEASE DETECTION INTERNATIONAL AND...
ACUSON CORPORATION FILES PATENT INFRINGEMENT LAWSUIT AGAINST HEWLETT-PACKARD
Respironics Announces Favorable Settlement of Bi-Level Patent Dispute.
Medtronic Sofamor Danek's Tyco Spine Cage Injunction Now in Effect Against Surgical Dynamics.
Biacore Awarded Damages in Patent Dispute.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters